Turja Chakrabarti
Medical Oncology Fellow City of Hope Comprehensive Cancer Center
Turja Chakrabarti, MD, MS is a senior Medical Oncology Fellow at City of Hope Comprehensive Cancer Center, where his research focuses on thoracic oncology, tumor immunology, and personalized cancer vaccine development. He serves as an investigator on a personalized mRNA neoantigen vaccine and on a neoantigen DNA vaccine trial for advanced lung cancer. His translational work integrates single-cell RNA sequencing, spatial transcriptomics, and deep learning, including IRIS, a model combining digital pathology and genomics to classify tumor immune phenotypes, to inform immunotherapy and vaccine strategies. Previously, Dr. Chakrabarti was Assistant Professor of Internal Medicine at UCSF and completed residency and chief residency at Johns Hopkins. He is also President and Founder of Pratit International, a global health nonprofit delivering cancer prevention and early detection services in underserved communities. He returns to the Summit after presenting in 2024.
Seminars
Establishing clinical trials for personalized cancer vaccines requires aligning regulatory strategy, patient selection, manufacturing logistics, and clinical operations within tight timelines. This workshop will explore practical approaches to trial design, manufacturing integration, immune monitoring, and regulatory planning, sharing key lessons learned to streamline execution and improve clinical development success.
Join this workshop to:
- Navigate regulatory pathways to accelerate approval timelines and reduce compliance risks
- Optimize patient selection strategies to improve enrollment rates and enhance trial outcomes
- Manage costs and resources to maximize budget efficiency and ensure trial sustainability
- Select clinical sites strategically to enhance patient recruitment and data quality
- Learn from trial outcomes to apply proven insights and avoid common pitfalls
- Reviewing experience as a physician in enrolling patients on cancer vaccine trials
- Discussing clinical challenges during vaccine manufacturing timeline
- Sharing cases on PCV candidates and patient sentiment surrounding PCV
